Boston Scientific reported positive, long-term data from the EVOLVE Trial of the Synergy everolimus-eluting bioabsorbable polymer platinum chromium coronary stent system, with no new major adverse cardiac events reported between years three and four. The study results were presented at EuroPCR 2015 by Prof. Ian Meredith, director of MonashHeart, at Monash Medical Centre in Melbourne, Australia.